SOPH
SOPHiA GENETICS SA4.8100
+0.0900+1.91%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Reaffirms ramps, flags expansions
Q&A largely reaffirmed prepared remarks' momentum but layered in ramp details for 2026's 20-22% growth guide. MSK-ACCESS has half its 70 customers live, with volumes ramping modestly; higher-ASPs like MSK-IMPACT Flex (2x average) and Enhanced Exomes fuel balance alongside hemonc strength. Biopharma renewals with AstraZeneca and a top-5 pharma add net positive lift this year, though long-cycle delays re-acceleration to 2027. Two giant US health systems already pipeline expansions toward 8-figure potential each. Implementation accelerated to record 102 last year. They'll add targeted US sales headcount. Ross prioritizes $100M+ scale via AI. Watch US ramps, biopharma traction.
Key Stats
Market Cap
326.34MP/E (TTM)
-Basic EPS (TTM)
-1.12Dividend Yield
0%IPO
Employees
Sector
Industry
CMHSF
COMPREHENSIVE HEALTHCARE SYS IN
0.35+0.00
DH
Definitive Healthcare Corp.
2.29-0.01
FORA
Forian Inc.
2.14+0.00
FOXO
FOXO Technologies Inc.
0.00+0.00
HCTI
Healthcare Triangle, Inc.
2.09-0.18
MYGN
Myriad Genetics, Inc.
6.88-0.11
OHCFF
LIGHT AI INC.
0.11+0.00
PHR
Phreesia, Inc.
16.35-0.35
TEM
Tempus AI, Inc.
68.11-0.56
WGS
GeneDx Holdings Corp.
141.72-8.89